Appendix 2—table 1. Post-hoc analyses of age and sex.
| Original analysis | Original analysis +age and sex | Age and sex only | ||||
|---|---|---|---|---|---|---|
| X 2 | p-Value | X2 | p-Value | X 2 | p-Value | |
| Putamen | ||||||
| Patients vs. controlsRight tremor-dominant Parkinson’s disease | 27.17 | 0.007 | 27.21 | 0.018 | 0.48 | 0.786 |
| UPDRS symptom severityRight tremor-dominant Parkinson’s disease | 22.28 | 0.035 | 23.46 | 0.053 | 2.38 | 0.305 |
| L-DOPA-placebo differenceLeft tremor-dominant Parkinson’s disease | 34.07 | 0.001 | 46.14 | <0.001 | 2.42 | 0.299 |
| L-DOPA-placebo differenceRight tremor-dominant Parkinson’s disease | 25.48 | 0.012 | 37.53 | 0.001 | 7.18 | 0.028 |
| Caudate-NAcc | ||||||
| Tobacco useHCP dataset | 49.55 | 0.002 | 53.56 | 0.001 | 1.04 | 0.594 |
| Alcohol useHCP dataset | 64.45 | <0.001 | 174.87 | <0.001 | 9.26 | 0.010 |
UPDRS = Unified Parkinson’s Disease Rating Scale; L-DOPA = levodopa-benserazide; HCP = Human Connectome Project; NAcc = nucleus accumbens.